<DOC>
	<DOCNO>NCT02468791</DOCNO>
	<brief_summary>The purpose study evaluate biosimilarity test product MabionCD20® reference product - MabThera® ( rituximab ) demonstrate comparative safety tolerability single course treatment MabionCD20® MabThera® patient moderate severe active rheumatoid arthritis .</brief_summary>
	<brief_title>MabionCD20® Compared MabThera® Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Subjects meet criterion participation study receive 2 intravenous infusion MabionCD20® MabThera® two week interval combination methotrexate folic acid . After treatment period , patient follow 24 week , order continue check safety . Therefore , total study last 48 week . There possibility repeat treatment 6 month first infusion subject meet retreatment criterion .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients active rheumatoid arthritis disease duration minimum 6 month prior screen visit Patients naive tumor necrosis factor ( TNF ) antagonists monoclonal antibody therapy Patients inadequate response adequate regimen methotrexate History current rheumatic autoimmune disease RA current inflammatory joint disease RA Contraindications accord MabThera SmPC every serious coexisting disease , Investigator 's opinion , would preclude subject participation Positive test HIV , hepatitis B surface antigen ( HBsAg ) AntiHBc antibody , hepatitis C antibody Prior treatment rituximab , antiCD20 mAb , antiTNFalpha drug monoclonal antibody Pregnancy lactation woman plan get pregnant course study and/or within 12 month post last study drug infusion Allergic reaction intolerance rituximab , MabionCD20 component Severe allergic anaphylactic reaction humanize murine monoclonal antibody previous treatment lymphocytedepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Rheumatic Diseases</keyword>
</DOC>